ImmunoPrecise Antibodies (CVE:IPA) Stock Price Up 0.8% – Still a Buy?

ImmunoPrecise Antibodies Ltd. (CVE:IPA)’s share price rose 0.8% during mid-day trading on Tuesday. The company traded as high as C$6.70 and last traded at C$6.50. Approximately 19,980 shares were traded during mid-day trading, an increase of 3% from the average daily volume of 19,376 shares. The stock had previously closed at C$6.45.

ImmunoPrecise Antibodies Stock Performance

The company has a quick ratio of 4.29, a current ratio of 5.06 and a debt-to-equity ratio of 1.70. The stock has a market cap of C$162.08 million and a price-to-earnings ratio of -7.30. The company has a 50 day simple moving average of C$6.50 and a 200 day simple moving average of C$6.50.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.